[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"patients-with-hematologic-disorders-after-allogeneic-hematopoietic-stem-cell-transplantation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:patients-with-hematologic-disorders-after-allogeneic-hematopoietic-stem-cell-transplantation":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":5},"100630108",false,"NCT07483385","Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\nParticipants must meet the following criteria:\n\n1. The patient signed an informed consent form and voluntarily participated in the study.\n2. Patients undergoing HLA haploidentical allogeneic hematopoietic stem cell transplantation;\n3. Age ≥18 years, regardless of gender\n4. ECOG score 0-2\n5. Expected survival ≥3 months\n6. No severe impairment of function of major organs\n\nExclusion Criteria:\n\nIf any of the following criteria are met, the participants must be excluded from this research project:\n\n1\\) Patients with known allergy to TPO-RAs; 2) Patients who cannot take oral medication due to gastrointestinal symptoms, altered mental status, etc. during transplantation; 3) Other reasons for exclusion as determined by the investigator.\n\n\\-","ALL","18 Years",{"count":17,"type":18},45,"ESTIMATED","INTERVENTIONAL",[21],"NA","This study is an investigator-initiated prospective, single-center, open-label clinical trial designed to evaluate the clinical efficacy and safety of Lusutrombopag in promoting platelet remodeling after allogeneic hematopoietic stem cell transplantation in patients with hematologic disorders.",[24,25],"Patients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation","Hematologic Disorders","RECRUITING","2026-03-22",{"date":29,"type":30},"2026-03-25","ACTUAL",{"date":32,"type":30},"2026-01-13",{"date":34,"type":18},"2028-01-28",{"name":36,"class":37},"The General Hospital of Western Theater Command","OTHER",""]